glp 1 drug side effects GI Adverse of Glucagon-Like Peptide-1 Receptor Agonists Ozempic and GLP-1 Drugs: Risk

The consistent results from sensitivity analyses using the Cox proportional hazards model with alternative sets of covariates and various exclusion criteria confirmed the robustness of our findings (Supplemental Table 8)

This broadened inclusion criteria allowed for a more comprehensive understanding of drug effects in high-risk groups and supported the expansion of GLP-1R agonist indications beyond glycemic control to include cardiovascular and renal benefits

Lancet 2016;387:67990.ArticlePubMed 80

Therefore, if the duration of diabetes and the follow-up observation period of the included study subjects are insufficient, it may be difficult to determine whether the absence of DR during the observation period is due to the protective effect of the drug or individual factors, potentially leading to false-positive or false-negative results

Delanaye P, Scheen AJ

No need to get caught up in all of those letters, although for the record, GIP stands for glucose-dependent insulinotropic polypeptide and GLP-1 stands for glucagon-like peptide-1